Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - canakinumab, quantity: 150 mg - diluent, not applicable - excipient ingredients: water for injections - ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (caps), in adults and children aged 2 years or older including: familial cold autoinflammatory syndrome (fcas) /familial cold urticaria (fcu); muckle-wells syndrome (mws); neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca). ilaris is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients aged 2 years or older.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - canakinumab - powder for solution for injection - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - canakinumab - solution for injection - 150mg/1ml

Canada - English - Health Canada

novartis pharmaceuticals canada inc - canakinumab - powder for solution - 150mg - canakinumab 150mg - immunosuppressive agents

Canada - English - Health Canada

novartis pharmaceuticals canada inc - canakinumab - solution - 150mg - canakinumab 150mg - immunosuppressive agents

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - canakinumab -

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

yousif mahmood hussain & bahrain pharmacy co - canakinumabum - powder for soln. for injection - 150

Philippines - English - FDA (Food And Drug Administration)

novartis healthcare philippines, inc. - canakinumab - lyophilized powder for solution for injection - 150mg / ml